Evaluation of Anti-aging Performance and Tolerance of a Hyaluronic Acid-based Filler NCTF135HA®

Inclusion Criteria: * Male or female subjects ≥19 years old; * Subject who has signed a written informed consent; * Subject with a Fitzpatrick phototype of I, II, III or IV * Subject with a grade of photoaging of 2 or 3 on a scale of Glogau * Subject having a wrinkle score according to Lemperle scale of 2, 3 or 4 at the level of periorbital lines * Subject having at least: * a Grade 1, 2, 3 or 4 on Bazin Neck Wrinkle Scale (at least N=30 subject for the control group) * or a Grade 2, 3 or 4 on Landau Décolleté Wrinkle Scale (at least N=30 subject for the control group) * Subject registered in social security system or other health insurance regimen * Subject accepting not to expose Him/herself to the sun or ultraviolet (UV) during the entire duration of the study. * Female subject accepting to take a pregnancy test. Exclusion Criteria: * Subject involved in any other clinical study evaluating drugs or medical devices or subjects in exclusion periods of another clinical study. * Subject deprived of freedom by an administrative or legal decision * Unable to follow protocol requirements. * Subject who has received indemnification of 4500 € during the 12 previous months for his/her participation in clinical trials (including participation in this study). * Subject having benefited from injection/facial implantation of any non-absorbable filling agent at any time of his/her life. * Subject having already had laser sessions for skin rejuvenation or a laser facelift in the previous year or a facelift by surgery in the 2 years prior to the study. * Subject with a history of fillers injections (hyaluronic acid type) in the last year or botulinum toxin in the last 6 months or the injectable implants (semi-permanent fillers) in the last two years. * Subject with a skin support device (wire mesh, gold wire, liquid silicone or other particulate material) at the study zones. * Subject having done a moderate to deep peeling or non-invasive rejuvenation techniques such as radiofrequency, ultrasound and lasers in the last 6 months. * Subject with a history of multiple severe allergies or anaphylactic shock. * Subject with a known hypersensitivity to hyaluronic acid, or other components of the NCTF 135HA solution. * Subject with known intolerance/hypersensitivity to any cosmetic topical products, hyaluronic acid and/or other components of Hydra-Filler ® FILORGA Moisturizing Cream. * Subject with a known hypersensitivity to chlorhexidine. * Subject with a known hypersensitivity to lidocaine or to local amide-type anesthetics * Prone to developing inflammatory skin conditions or hypertrophic scarring according to investigator judgement. * Subject with a history of streptococcal diseases (angina recurrent, rheumatic fever). * Subject under concomitant treatment (or not stopped for at least 3 months) by oral or injectable corticosteroid (inhaled corticosteroids are allowed as well as a topical corticotherapy not involving the study zones). * Subject under concomitant treatment (or not stopped for at least 1 year) by immunosuppressive or chemotherapy treatments. * Subject with a history of less than one year of radiation therapy at the head and neck. * Subject with an associated antecedent or pathology of autoimmune or connective tissue disease. * Subject presenting a skin pathology, an acute inflammatory reaction or a bacterial or viral infection on the study zones or within the 6 weeks after the end of such an episode. * Subject having taken aspirin or anticoagulants, at regular doses, in the last 15 days preceding the act. * Subject that has been exposed to sun or UV in the last 15 days. * Subject with a dermatological condition or inflammation at the treatment zone or near to this area (according to the investigator's judgment). * Pregnant or lactating woman (Before every injection, a urinary pregnancy test will be performed). * Subject having epilepsy uncontrolled by treatment. * Subject presenting a general pathology, skin pathology, dermatosis, systemic, chronic or acute disease and/or topical or general treatment that in the opinion of the investigator may interfere with the treatment or compromise the participation of the subject in the study.